Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for moderate rheumatoid arthritis after conventional DMARDs have failed (partial review of TA375) – appraisal consultation document

DRAFT NICE guidance recommends adalimumab and infliximab, both with methotrexate, for active rheumatoid arthritis in adults, only if the disease has responded inadequately to intensive therapy with 2 or more conventional DMARDs and the DAS28 score is 3.2-5.1.

SPS commentary:

Abatacept and etanercept were not recommended.  If approved, this would be the second technology appraisal recommending use of advanced therapies for the expanded use in moderate arthritis (DAS 3.2-5.1), following NICE TA676 for filgotinib.

Source:

National Institute for Health and Care Excellence

Resource links:

NICE TA676